相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
Mark T. Osterman et al.
GASTROENTEROLOGY (2014)
The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A single academic center case series
Anita Afzali et al.
JOURNAL OF CROHNS & COLITIS (2014)
Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis
D. van der Heijde et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2014)
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Infliximab for Crohn's Disease: The First 500 Patients Followed Up Through 2009
Jennifer L. Seminerio et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial
Koji Yoshida et al.
INFLAMMATORY BOWEL DISEASES (2012)
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease
M. A. Kamm et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti-Tumor Necrosis Factor Therapy
Jean-Francois Rahier et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Correlation Between the Crohn's Disease Activity and Harvey-Bradshaw Indices in Assessing Crohn's Disease Severity
Severine Vermeire et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Predictors of premature discontinuation of treatment in multiple disease states
Eric Nantz et al.
Patient Preference and Adherence (2010)
Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years
Maria H. Lonnkvist et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Bacterial and opportunistic infections during anti-TNF therapy
Anja Strangfeld et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
European evidence based consensus on the diagnosis and management of Crohn's disease:: current management
SPL Travis et al.
GUT (2006)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
